Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 Dec;34(12):2318–2326. doi: 10.1128/aac.34.12.2318

Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent.

D Gargallo-Viola 1, M Esteve 1, M Moros 1, R Coll 1, M A Xicota 1, C de Andres 1, R Roser 1, J Guinea 1
PMCID: PMC172054  PMID: 2088187

Abstract

E-4502, E-4501, E-4500, E-4480, E-4474, and E-4441 are new monofluorinated or difluorinated quinolone agents that are chemically characterized by the presence of an azetidin ring, with different C'-3 substituents, at position 7 of the molecular structure. The MICs of the difluorinated compounds E-4501, E-4474, and E-4441 for 90% of isolates were 0.06 to 1, 0.06 to 1, and 0.12 to 1 microgram/ml, respectively, against gram-positive organisms (staphylococci, streptococci, and Enterococcus faecalis); 0.0015 to 0.12, 0.015 to 0.12, and 0.03 to 0.12 microgram/ml, respectively, against members of the family Enterobacteriaceae except Providencia spp.; and 1, 1, and 2 micrograms/ml, respectively, against Pseudomonas aeruginosa. E-4501, E-4474, and E-4441 inhibited all anaerobic bacteria at concentrations of 1, 2, and 4 micrograms/ml, respectively. Difluorinated compounds were significantly more active than the corresponding monofluorinated analogs E-4502, E-4500, and E-4480 against aerobic and facultatively anaerobic organisms, as well as against anaerobes. Considering monofluorinated and difluorinated compounds, activity in moderate ascending order was observed in quinolones containing an amine and a methyl group (E-4441 and E-4480), an amine group (E-4474 and E-4500), and a methylamine group (E-4501 and E-4502) in the C'-3 position of the azetidin ring. E-4501, E-4474, and E-4441 were more active than norfloxacin and DR-3355 [S-(-)-ofloxacin], had activities comparable to or slightly lower than that of ciprofloxacin against gram-negative bacteria, and were more active than all the reference quinolones against gram-positive organisms and anaerobes. E-4502 and E-4501, which were used to determine the effect of pH, were less active in acidic medium. In general, E-4502, E-4501, E-4500, E-4480, E-4474, and E-4441 activities were not affected or increased in medium containing serum but decreased in the presence of 10 mM Mg2+ or in human urine at pH 5.5. The protective effect of E-4501, E-4474, and E-4441 after oral administration against systemic infections with Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa in mice was greater than that of ciprofloxacin.

Full text

PDF
2318

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asahara M., Tsuji A., Goto S., Masuda K., Kiuchi A. In vitro and in vivo activities of QA-241, a new tricyclic quinolone derivative. Antimicrob Agents Chemother. 1989 Aug;33(8):1144–1152. doi: 10.1128/aac.33.8.1144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chin N. X., Brittain D. C., Neu H. C. In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone. Antimicrob Agents Chemother. 1986 Apr;29(4):675–680. doi: 10.1128/aac.29.4.675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chu D. T., Fernandes P. B., Claiborne A. K., Pihuleac E., Nordeen C. W., Maleczka R. E., Jr, Pernet A. G. Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents. J Med Chem. 1985 Nov;28(11):1558–1564. doi: 10.1021/jm00149a003. [DOI] [PubMed] [Google Scholar]
  4. Chu D. T., Fernandes P. B. Structure-activity relationships of the fluoroquinolones. Antimicrob Agents Chemother. 1989 Feb;33(2):131–135. doi: 10.1128/aac.33.2.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Coll R., Esteve M., Moros M., Xicota M. A., Parés J. In vitro antibacterial activity of irloxacin (E-3432) on clinical isolates. Drugs Exp Clin Res. 1987;13(2):75–77. [PubMed] [Google Scholar]
  6. Domagala J. M., Hanna L. D., Heifetz C. L., Hutt M. P., Mich T. F., Sanchez J. P., Solomon M. New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. J Med Chem. 1986 Mar;29(3):394–404. doi: 10.1021/jm00153a015. [DOI] [PubMed] [Google Scholar]
  7. Fernandes P. B., Chu D. T., Swanson R. N., Ramer N. R., Hanson C. W., Bower R. R., Stamm J. M., Hardy D. J. A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1988 Jan;32(1):27–32. doi: 10.1128/aac.32.1.27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fung-Tomc J., Desiderio J. V., Tsai Y. H., Warr G., Kessler R. E. In vitro and in vivo antibacterial activities of BMY 40062, a new fluoronaphthyridone. Antimicrob Agents Chemother. 1989 Jun;33(6):906–914. doi: 10.1128/aac.33.6.906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gargallo D., Moros M., Coll R., Esteve M., Parés J., Xicota M. A., Guinea J. Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats. Antimicrob Agents Chemother. 1988 May;32(5):636–641. doi: 10.1128/aac.32.5.636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Goueffon Y., Montay G., Roquet F., Pesson M. Sur un nouvel antibactérien de synthèse : l'acide éthyl-1 fluoro-6 (méthyl-4 pipérazinyl-1)-7 oxo-4 dihydro-1.4 quinoléine-3 carboxylique (1589 R.B.). C R Seances Acad Sci III. 1981 Jan 5;292(1):37–40. [PubMed] [Google Scholar]
  11. Hardy D. J., Swanson R. N., Hensey D. M., Ramer N. R., Bower R. R., Hanson C. W., Chu D. T., Fernandes P. B. Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones. Antimicrob Agents Chemother. 1987 Nov;31(11):1768–1774. doi: 10.1128/aac.31.11.1768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hirose T., Okezaki E., Kato H., Ito Y., Inoue M., Mitsuhashi S. In vitro and in vivo activity of NY-198, a new difluorinated quinolone. Antimicrob Agents Chemother. 1987 Jun;31(6):854–859. doi: 10.1128/aac.31.6.854. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hooper D. C., Wolfson J. S. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother. 1985 Nov;28(5):716–721. doi: 10.1128/aac.28.5.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Koga H., Itoh A., Murayama S., Suzue S., Irikura T. Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids. J Med Chem. 1980 Dec;23(12):1358–1363. doi: 10.1021/jm00186a014. [DOI] [PubMed] [Google Scholar]
  15. Nakamura S., Minami A., Nakata K., Kurobe N., Kouno K., Sakaguchi Y., Kashimoto S., Yoshida H., Kojima T., Ohue T. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother. 1989 Aug;33(8):1167–1173. doi: 10.1128/aac.33.8.1167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Reeves D. S., Bywater M. J., Holt H. A. The activity of enoxacin against clinical bacterial isolates in comparison with that of five other agents, and factors affecting that activity. J Antimicrob Chemother. 1984 Sep;14 (Suppl 100):7–17. doi: 10.1093/jac/14.suppl_c.7. [DOI] [PubMed] [Google Scholar]
  17. Sato K., Matsuura Y., Inoue M., Une T., Osada Y., Ogawa H., Mitsuhashi S. In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrob Agents Chemother. 1982 Oct;22(4):548–553. doi: 10.1128/aac.22.4.548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Smith S. M., Eng R. H., Cherubin C. E. Conditions affecting the results of susceptibility testing for the quinolone compounds. Chemotherapy. 1988;34(4):308–314. doi: 10.1159/000238584. [DOI] [PubMed] [Google Scholar]
  19. Une T., Fujimoto T., Sato K., Osada Y. In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother. 1988 Sep;32(9):1336–1340. doi: 10.1128/aac.32.9.1336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Walker R. C., Wright A. J. Symposium on antimicrobial agents. The quinolones. Mayo Clin Proc. 1987 Nov;62(11):1007–1012. doi: 10.1016/s0025-6196(12)65073-3. [DOI] [PubMed] [Google Scholar]
  21. Wentland M. P., Bailey D. M., Cornett J. B., Dobson R. A., Powles R. G., Wagner R. B. Novel amino-substituted 3-quinolinecarboxylic acid antibacterial agents: synthesis and structure-activity relationships. J Med Chem. 1984 Sep;27(9):1103–1108. doi: 10.1021/jm00375a003. [DOI] [PubMed] [Google Scholar]
  22. Wise R., Andrews J. M., Ashby J. P., Matthews R. S. In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents. Antimicrob Agents Chemother. 1988 May;32(5):617–622. doi: 10.1128/aac.32.5.617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Wise R., Andrews J. M., Edwards L. J. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother. 1983 Apr;23(4):559–564. doi: 10.1128/aac.23.4.559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Wise R., Ashby J. P., Andrews J. M. In vitro activity of PD 127,391, an enhanced-spectrum quinolone. Antimicrob Agents Chemother. 1988 Aug;32(8):1251–1256. doi: 10.1128/aac.32.8.1251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Wolfson J. S., Hooper D. C. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989 Oct;2(4):378–424. doi: 10.1128/cmr.2.4.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Wolfson J. S., Hooper D. C. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985 Oct;28(4):581–586. doi: 10.1128/aac.28.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Xicota M. A., Coll R., Esteve M., Moros M., Parés J. In vitro antibacterial activity of E-3604, a new 6-fluoroquinolone, on clinical isolates. Drugs Exp Clin Res. 1987;13(3):133–136. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES